AG˹ٷ

STOCK TITAN

[Form 4] Pinterest, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Amended Form 4 highlights � Inhibikase Therapeutics (IKT) director Vincent Aurentz filed a Form 4/A dated 07/02/2025 to correct the exercise price of a previously reported option grant.

  • Instrument: Stock option for 134,427 common shares.
  • Corrected exercise price: $2.97 per share (previous filing reported an incorrect price).
  • Grant date: 02/21/2025  |  Expiration: 02/21/2035.
  • Vesting schedule: 50% on the first anniversary and 50% on the second anniversary of the grant date, contingent on continued service.
  • Ownership form: Direct; no shares were bought or sold in the open market, so the company’s share count and public float are unchanged.

This filing is administrative in nature, rectifying a clerical error. It does not indicate any change in the director’s net exposure or signal new information about Inhibikase’s operations or financial outlook.

Principali modifiche nel Modulo 4 rettificato � Vincent Aurentz, direttore di Inhibikase Therapeutics (IKT), ha presentato un Modulo 4/A datato 02/07/2025 per correggere il prezzo di esercizio di un'opzione precedentemente comunicata.

  • Strumento: Opzione su azioni per 134.427 azioni ordinarie.
  • Prezzo di esercizio corretto: 2,97 $ per azione (la precedente comunicazione riportava un prezzo errato).
  • Data di concessione: 21/02/2025  |  Scadenza: 21/02/2035.
  • Piano di maturazione: 50% al primo anniversario e 50% al secondo anniversario della data di concessione, subordinato alla permanenza in servizio.
  • Forma di proprietà: Diretta; non sono state acquistate o vendute azioni sul mercato aperto, quindi il numero di azioni della società e il flottante pubblico rimangono invariati.

Questa comunicazione ha natura amministrativa e corregge un errore materiale. Non indica alcuna variazione nell’esposizione netta del direttore né segnala nuove informazioni sulle operazioni o le prospettive finanziarie di Inhibikase.

Aspectos destacados del Formulario 4 enmendado � Vincent Aurentz, director de Inhibikase Therapeutics (IKT), presentó un Formulario 4/A fechado el 02/07/2025 para corregir el precio de ejercicio de una concesión de opción reportada previamente.

  • Instrumento: Opción sobre acciones para 134,427 acciones ordinarias.
  • Precio de ejercicio corregido: 2,97 $ por acción (el informe anterior contenía un precio incorrecto).
  • Fecha de concesión: 21/02/2025  |  Vencimiento: 21/02/2035.
  • Calendario de adquisición: 50% en el primer aniversario y 50% en el segundo aniversario de la fecha de concesión, condicionado a la continuidad del servicio.
  • Forma de propiedad: Directa; no se compraron ni vendieron acciones en el mercado abierto, por lo que el número de acciones de la compañía y el flotante público permanecen sin cambios.

Esta presentación es de naturaleza administrativa y corrige un error clerical. No indica ningún cambio en la exposición neta del director ni señala nueva información sobre las operaciones o perspectivas financieras de Inhibikase.

수정� Form 4 주요 내용 � Inhibikase Therapeutics(IKT) 이사 Vincent Aurentz가 2025� 7� 2일자 Form 4/A� 제출하여 이전� 보고� 옵션 부여의 행사 가격을 수정했습니다.

  • 수단: 보통� 134,427주에 대� 스톡 옵션.
  • 수정� 행사 가�: 주당 2.97달러 (이전 제출서에� 잘못� 가격이 보고�).
  • 붶여일: 2025� 2� 21�  |  만료�: 2035� 2� 21�.
  • 베스� 일정: 붶여일로부� 1주년� 2주년� 각각 50%�, 계속 근무 조건 하에.
  • 소유 형태: 직접 소유; 공개 시장에서 주식� 매매하지 않아 회사� � 주식 수와 공개 유통 주식 수는 변� 없음.

이번 제출은 행정적인 성격으로, 단순� 서류상의 오류� 수정� 것입니다. 이는 이사� � 노출� 변동이 있음� 의미하지 않으�, Inhibikase� 운영이나 재무 전망� 대� 새로� 정보� 나타내지 않습니다.

Points clés du formulaire 4 modifié � Vincent Aurentz, administrateur d'Inhibikase Therapeutics (IKT), a déposé un formulaire 4/A daté du 02/07/2025 afin de corriger le prix d'exercice d'une attribution d'option précédemment déclarée.

  • Instrument : Option d'achat portant sur 134 427 actions ordinaires.
  • Prix d'exercice corrigé : 2,97 $ par action (le dépôt précédent indiquait un prix incorrect).
  • Date d'attribution : 21/02/2025  |  Expiration : 21/02/2035.
  • Calendrier d'acquisition : 50 % au premier anniversaire et 50 % au deuxième anniversaire de la date d'attribution, sous réserve de la poursuite du service.
  • Forme de propriété : Directe ; aucune action n'a été achetée ou vendue sur le marché ouvert, donc le nombre d'actions de la société et le flottant public restent inchangés.

Ce dépôt est de nature administrative, corrigeant une erreur matérielle. Il n'indique aucun changement dans l'exposition nette de l'administrateur ni ne signale de nouvelles informations concernant les opérations ou les perspectives financières d'Inhibikase.

Wesentliche Änderungen im geänderten Formular 4 � Vincent Aurentz, Direktor von Inhibikase Therapeutics (IKT), reichte am 02.07.2025 ein Formular 4/A ein, um den Ausübungspreis einer zuvor gemeldeten Optionszuteilung zu korrigieren.

  • Instrument: Aktienoption für 134.427 Stammaktien.
  • Korrigierter Ausübungspreis: 2,97 $ pro Aktie (im vorherigen Bericht war ein falscher Preis angegeben).
  • Zuteilungsdatum: 21.02.2025  |  Ablaufdatum: 21.02.2035.
  • Vesting-Zeitplan: 50 % am ersten Jahrestag und 50 % am zweiten Jahrestag des Zuteilungsdatums, vorbehaltlich fortgesetzter Dienstzeit.
  • Besitzform: Direkt; es wurden keine Aktien am offenen Markt gekauft oder verkauft, daher bleiben die Aktienanzahl und der Streubesitz des Unternehmens unverändert.

Diese Einreichung ist administrativer Natur und korrigiert einen Schreibfehler. Sie signalisiert keine Änderung des Nettoengagements des Direktors und enthält keine neuen Informationen über die Geschäftstätigkeit oder die finanzielle Prognose von Inhibikase.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Administrative correction; no cash outflow, dilution, or trading activity—neutral for shareholders.

The Form 4/A merely adjusts the exercise price of an existing option grant to $2.97. Because the options remain unexercised and vest over two years, the filing has no immediate balance-sheet or cash-flow impact. Share count dilution occurs only upon future exercise and at a premium to today’s sub-$3 price level. The correction underscores compliance quality but carries minimal valuation relevance.

TL;DR: Filing corrects prior error, reflects sound disclosure practice; governance impact neutral.

Promptly amending insider filings when errors surface is a governance positive, but the underlying transaction—an at-market option grant—is routine. No Rule 10b5-1 plan is invoked, and no sale or purchase occurred, limiting market-moving significance. The two-year vesting aligns director incentives with long-term performance. Overall impact on governance risk profile is negligible.

Principali modifiche nel Modulo 4 rettificato � Vincent Aurentz, direttore di Inhibikase Therapeutics (IKT), ha presentato un Modulo 4/A datato 02/07/2025 per correggere il prezzo di esercizio di un'opzione precedentemente comunicata.

  • Strumento: Opzione su azioni per 134.427 azioni ordinarie.
  • Prezzo di esercizio corretto: 2,97 $ per azione (la precedente comunicazione riportava un prezzo errato).
  • Data di concessione: 21/02/2025  |  Scadenza: 21/02/2035.
  • Piano di maturazione: 50% al primo anniversario e 50% al secondo anniversario della data di concessione, subordinato alla permanenza in servizio.
  • Forma di proprietà: Diretta; non sono state acquistate o vendute azioni sul mercato aperto, quindi il numero di azioni della società e il flottante pubblico rimangono invariati.

Questa comunicazione ha natura amministrativa e corregge un errore materiale. Non indica alcuna variazione nell’esposizione netta del direttore né segnala nuove informazioni sulle operazioni o le prospettive finanziarie di Inhibikase.

Aspectos destacados del Formulario 4 enmendado � Vincent Aurentz, director de Inhibikase Therapeutics (IKT), presentó un Formulario 4/A fechado el 02/07/2025 para corregir el precio de ejercicio de una concesión de opción reportada previamente.

  • Instrumento: Opción sobre acciones para 134,427 acciones ordinarias.
  • Precio de ejercicio corregido: 2,97 $ por acción (el informe anterior contenía un precio incorrecto).
  • Fecha de concesión: 21/02/2025  |  Vencimiento: 21/02/2035.
  • Calendario de adquisición: 50% en el primer aniversario y 50% en el segundo aniversario de la fecha de concesión, condicionado a la continuidad del servicio.
  • Forma de propiedad: Directa; no se compraron ni vendieron acciones en el mercado abierto, por lo que el número de acciones de la compañía y el flotante público permanecen sin cambios.

Esta presentación es de naturaleza administrativa y corrige un error clerical. No indica ningún cambio en la exposición neta del director ni señala nueva información sobre las operaciones o perspectivas financieras de Inhibikase.

수정� Form 4 주요 내용 � Inhibikase Therapeutics(IKT) 이사 Vincent Aurentz가 2025� 7� 2일자 Form 4/A� 제출하여 이전� 보고� 옵션 부여의 행사 가격을 수정했습니다.

  • 수단: 보통� 134,427주에 대� 스톡 옵션.
  • 수정� 행사 가�: 주당 2.97달러 (이전 제출서에� 잘못� 가격이 보고�).
  • 붶여일: 2025� 2� 21�  |  만료�: 2035� 2� 21�.
  • 베스� 일정: 붶여일로부� 1주년� 2주년� 각각 50%�, 계속 근무 조건 하에.
  • 소유 형태: 직접 소유; 공개 시장에서 주식� 매매하지 않아 회사� � 주식 수와 공개 유통 주식 수는 변� 없음.

이번 제출은 행정적인 성격으로, 단순� 서류상의 오류� 수정� 것입니다. 이는 이사� � 노출� 변동이 있음� 의미하지 않으�, Inhibikase� 운영이나 재무 전망� 대� 새로� 정보� 나타내지 않습니다.

Points clés du formulaire 4 modifié � Vincent Aurentz, administrateur d'Inhibikase Therapeutics (IKT), a déposé un formulaire 4/A daté du 02/07/2025 afin de corriger le prix d'exercice d'une attribution d'option précédemment déclarée.

  • Instrument : Option d'achat portant sur 134 427 actions ordinaires.
  • Prix d'exercice corrigé : 2,97 $ par action (le dépôt précédent indiquait un prix incorrect).
  • Date d'attribution : 21/02/2025  |  Expiration : 21/02/2035.
  • Calendrier d'acquisition : 50 % au premier anniversaire et 50 % au deuxième anniversaire de la date d'attribution, sous réserve de la poursuite du service.
  • Forme de propriété : Directe ; aucune action n'a été achetée ou vendue sur le marché ouvert, donc le nombre d'actions de la société et le flottant public restent inchangés.

Ce dépôt est de nature administrative, corrigeant une erreur matérielle. Il n'indique aucun changement dans l'exposition nette de l'administrateur ni ne signale de nouvelles informations concernant les opérations ou les perspectives financières d'Inhibikase.

Wesentliche Änderungen im geänderten Formular 4 � Vincent Aurentz, Direktor von Inhibikase Therapeutics (IKT), reichte am 02.07.2025 ein Formular 4/A ein, um den Ausübungspreis einer zuvor gemeldeten Optionszuteilung zu korrigieren.

  • Instrument: Aktienoption für 134.427 Stammaktien.
  • Korrigierter Ausübungspreis: 2,97 $ pro Aktie (im vorherigen Bericht war ein falscher Preis angegeben).
  • Zuteilungsdatum: 21.02.2025  |  Ablaufdatum: 21.02.2035.
  • Vesting-Zeitplan: 50 % am ersten Jahrestag und 50 % am zweiten Jahrestag des Zuteilungsdatums, vorbehaltlich fortgesetzter Dienstzeit.
  • Besitzform: Direkt; es wurden keine Aktien am offenen Markt gekauft oder verkauft, daher bleiben die Aktienanzahl und der Streubesitz des Unternehmens unverändert.

Diese Einreichung ist administrativer Natur und korrigiert einen Schreibfehler. Sie signalisiert keine Änderung des Nettoengagements des Direktors und enthält keine neuen Informationen über die Geschäftstätigkeit oder die finanzielle Prognose von Inhibikase.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Silbermann Benjamin

(Last) (First) (Middle)
C/O PINTEREST, INC.
651 BRANNAN STREET

(Street)
SAN FRANCISCO CA 94107

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PINTEREST, INC. [ PINS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/02/2025 C(1) 83,333 A $0 83,333 I Benjamin and Divya Silbermann Family Trust
Class A Common Stock 07/02/2025 S(2) 38,445 D $35.1729(3) 44,888 I Benjamin and Divya Silbermann Family Trust
Class A Common Stock 07/02/2025 S(2) 44,888 D $35.6116(4) 0 I Benjamin and Divya Silbermann Family Trust
Class A Common Stock 07/02/2025 C(1) 18,750 A $0 18,750 I SFTC, LLC(5)
Class A Common Stock 07/02/2025 S(2) 8,484 D $35.1647(6) 10,266 I SFTC, LLC(5)
Class A Common Stock 07/02/2025 S(2) 10,266 D $35.6049(7) 0 I SFTC, LLC(5)
Class A Common Stock 8,414(8) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock (9) 07/02/2025 C(1) 83,333 (9) (9) Class A Common Stock 83,333 $0 36,570,226 I Benjamin and Divya Silbermann Family Trust
Class B Common Stock (9) 07/02/2025 C(1) 18,750 (9) (9) Class A Common Stock 18,750 $0 8,950,030 I SFTC, LLC(5)
Class B Common Stock (9) (9) (9) Class A Common Stock 1,174,715 1,174,715 D
Explanation of Responses:
1. Represents the conversion of shares of Class B Common Stock, par value $0.00001 ("Class B Common Stock") into Class A Common Stock, par value $0.00001 ("Class A Common Stock"), in connection with the sale of such shares pursuant to a Rule 10b5-1 trading plan.
2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2024.
3. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $34.8650 to $35.4150 per share. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.4200 to $36.0450 per share. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. Mr. Silbermann disclaims beneficial ownership of the shares held by the SFTC, LLC, a Delaware limited liability company owned by The Silbermann 2012 Irrevocable Trust. This report shall not be deemed an admission that he is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in such shares by virtue of certain of his immediate family members' interests in The Silbermann 2012 Irrevocable Trust.
6. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $34.8550 to $35.4000 per share. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.4100 to $36.0300 per share. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. Represents previously reported RSUs that are subject to vesting requirements.
9. Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of the Class A Common Stock. Additionally, each share of Class B Common Stock will, subject to certain exceptions, convert automatically into one share of Class A Common Stock upon any transfer, and in other circumstances as outlined in the Issuer's Certificate of Incorporation.
Remarks:
Jacquie Katzel, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Pinterest

NYSE:PINS

PINS Rankings

PINS Latest News

PINS Latest SEC Filings

PINS Stock Data

23.77B
589.88M
0.62%
91.56%
3.51%
Internet Content & Information
Services-computer Programming, Data Processing, Etc.
United States
SAN FRANCISCO